

Title	Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis
Author(s)	Takahashi, Yuka; Kameda, Hiraku; Miya, Aika; Nomoto, Hiroshi; Cho, Kyu Yong; Nakamura, Akinobu; Nishimura, Hiroki; Kimura, Hirokazu; Suzuki, Masaru; Konno, Satoshi; Shimizu, Ai; Matsuno, Yoshihiro; Okamoto, Michinari; Motegi, Hiroaki; Iwata, Naoko; Fujisawa, Haruki; Suzuki, Atsushi; Sugimura, Yoshihisa; Miyoshi, Hideaki; Atsumi, Tatsuya
Citation	Pituitary, 25(2), 321-327 https://doi.org/10.1007/s11102-021-01200-0
Issue Date	2023-04-06
Doc URL	http://hdl.handle.net/2115/88787
Rights	This is a post-peer-review, pre-copyedit version of an article published in Pituitary. The final authenticated version is available online at: http://dx.doi.org/10.1007/s11102-021-01200-0.
Туре	article (author version)
File Information	Pituitary 25 321–327.pdf



Instructions for use

1	Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary
2	sarcoidosis
3	
4	Running head: Lymphocytic panhypophysitis with sarcoidosis
5	
6	Yuka Takahashi <sup>1</sup> , Hiraku Kameda <sup>1</sup> , Aika Miya <sup>1</sup> , Hiroshi Nomoto <sup>1</sup> , Kyu Yong Cho <sup>1</sup> ,
7	Akinobu Nakamura <sup>1</sup> , Hiroki Nishimura <sup>2</sup> , Hirokazu Kimura <sup>2</sup> , Masaru Suzuki <sup>2</sup> , Satoshi
8	Konno <sup>2</sup> , Ai Shimizu <sup>3</sup> , Yoshihiro Matsuno <sup>3</sup> , Michinari Okamoto <sup>4</sup> , Hiroaki Motegi <sup>4</sup> , Naoko
9	Iwata <sup>5, 7</sup> , Haruki Fujisawa <sup>5</sup> , Atsushi Suzuki <sup>5</sup> , Yoshihisa Sugimura <sup>5</sup> , Hideaki Miyoshi <sup>1,6</sup> ,
10	Tatsuya Atsumi <sup>1</sup>
11	
12	<sup>1</sup> Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and
13	Graduate School of Medicine, Hokkaido University, Sapporo, Japan
14	<sup>2</sup> Department of Respiratory Medicine, Faculty of Medicine and Graduate School of
15	Medicine, Hokkaido University, Sapporo, Japan
16	<sup>3</sup> Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan
17	<sup>4</sup> Department of Neurosurgery, Graduate School of Medicine, Hokkaido University,
18	Sapporo, Japan
19	<sup>5</sup> Department of Endocrinology, Diabetes and Metabolism, Fujita Health University,
20	Toyoake, Japan
21	<sup>6</sup> Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine,
22	Hokkaido University, Sapporo, Japan
23	<sup>7</sup> Department of Endocrinology and Diabetes, Daido Hospital, Nagoya, Japan
24	

- 25 Correspondence to: Hiraku Kameda, MD, PhD
- 26 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and
- 27 Graduate School of Medicine, Hokkaido University Graduate School of Medicine, N-15,
- 28 W-7, Kita-ku, Sapporo 060-8638, Japan.
- 29 Tel: +81-11-706-5915; Fax: +81-11-706-7710; E-mail: <u>hkameda@huhp.hokudai.ac.jp</u>

- 31 Abstract
- 32

Purpose: To explore the clinical significance of anti-rabphillin-3A antibody for the
 differential diagnosis of lymphocytic panhypophysitis.

35 Methods and Results: A 58-year-old Japanese man developed uveitis of unknown cause in 2017. In 2019, he became aware of polyuria. In August 2020, he noticed transient 36 37 diplopia and was diagnosed with right abducens nerve palsy. At the same time, he complained of fatigue and loss of appetite. Head magnetic resonance imaging 38 39 demonstrated enlargement of the pituitary stalk and pituitary gland, corresponding to 40 hypophysitis. Hormone stimulation tests showed blunted responses with respect to all 41 anterior pituitary hormones. Central diabetes insipidus was diagnosed on the basis of a 42 hypertonic saline loading test. Taking these findings together, a diagnosis of 43 panhypopituitarism was made. Computed tomography showed enlargement of hilar 44 lymph nodes. Biopsies of the hilar lymph nodes revealed non-caseating epithelioid cell 45 granulomas that were consistent with sarcoidosis. Biopsy of the anterior pituitary revealed mild lymphocyte infiltration in the absence of IgG4-positive cells, non-caseating 46 47 granulomas, or neoplasia. Western blotting revealed the presence of anti-rabphilin-3A 48 antibody, supporting a diagnosis of lymphocytic panhypophysitis. Because the patient 49 had no visual impairment or severe uveitis, we continued physiological hormone 50 replacement therapy and topical steroid therapy for the uveitis.

51 Conclusion: To the best of our knowledge, this is the first case of anti-rabphilin 3A 52 antibody positive lymphocytic panhypophysitis comorbid with sarcoidosis, diagnosed by 53 both pituitary and hilar lymph node biopsy. The utility of anti-rabphilin-3A antibody for 54 the differential diagnosis of hypophysitis like this case should be clarified with further

- 55 case studies.
- 56
- 57 Keywords: lymphocytic panhypophysitis, sarcoidosis, anti-rabphilin-3a antibody,
- 58 panhypopituitarism

### 59 Introduction

Lymphocytic hypophysitis (LH) is a chronic inflammatory disease in which 60 61 lymphocytes mainly infiltrate the anterior or posterior pituitary gland and/or the hypothalamic infundibulum, and this is associated with the presence of other autoimmune 62 63 diseases. Because positivity for various autoantibodies occurs in some cases, an autoimmune mechanism has been considered for LH. LH is classified on the basis of 64 pathological findings with respect to inflammation [1-5]. (1) Lymphocytic 65 adenohypophysitis (LAH) is characterized by inflammatory lesions in the anterior 66 67 pituitary gland and lower secretion of anterior pituitary hormones. (2) Lymphocytic 68 infundibuloneurohypophysitis (LINH) presents with central diabetes insipidus, owing to 69 localized inflammation in the stalk and posterior lobe. (3) Lymphocytic panhypophysitis 70 (LPH) involves inflammation of the entire pituitary and is characterized by clinical 71 features of both LAH and LINH. Although a definitive diagnosis requires the pathological 72 assessment of a pituitary biopsy, biopsies are often difficult to collect. Furthermore, even 73 if a pituitary biopsy is performed, it is difficult to distinguish LH from other diseases that 74 cause inflammation in the suprasellar region, including craniopharyngioma, Rathke cleft 75 cysts, sarcoidosis, infectious diseases, and germinoma. Here, we report a case of LPH 76 with comorbid pulmonary sarcoidosis that was diagnosed on the basis of pathological 77 findings in both the pituitary gland and hilar lymph node. In this patient, the autoantibody 78 profile was investigated.

79

```
80 Case report
```

81 A 58-year-old Japanese man was diagnosed with uveitis of unknown cause at a 82 local hospital in 2017. Then, in 2019, he became aware of polyuria. In August 2020, he

83 experienced transient diplopia and was diagnosed with right abducens nerve palsy. He 84 also reported fatigue and a loss of appetite. At that time, he underwent head magnetic 85 resonance imaging (MRI), which revealed enlargement of the pituitary stalk and gland. Hypophysitis was suspected to be the cause of the diplopia, fatigue, and loss of appetite. 86 87 Physical examination was unremarkable and the patient had no family history of endocrinological disorder. No abnormal findings were made during 12-lead 88 89 electrocardiography or echocardiography. In addition, there were no obvious 90 hematological or biochemical abnormalities, but there were reductions in the serum 91 concentrations of all the anterior pituitary hormones, which was suggestive of 92 panhypopituitarism (Table 1). Pituitary biopsy was performed on admission with 93 hydrocortisone drip 100 mg for the prevention of adrenal insufficiency, followed by a 94 physiological dose of oral hydrocortisone. Because the patient's polyuria worsened after 95 the administration of hydrocortisone, we prescribed oral desmopressin 60 µg/day. 96 Levothyroxine was also started 7 days after the hydrocortisone administration.

A growth hormone releasing peptide-2 (GHRP-2) loading test showed a poor response of growth hormone. therefore, severe adult growth hormone deficiency was diagnosed. A rapid ACTH stimulation test also revealed a poor cortisol secretory response, suggesting adrenal insufficiency. In a hypertonic saline loading test, antidiuretic hormone (ADH) was not secreted in response to an increase in serum Na, which led to a diagnosis of central diabetes insipidus. On the basis of these findings, the patient was diagnosed with panhypopituitarism.

104 Thoracoabdominal computed tomography showed swelling of the patient's 105 longitudinal and hilar lymph nodes, but there were no findings suggestive of malignant 106 tumors (Fig. 1A–E). A biopsy of the pituitary gland demonstrated mild lymphocytic 107 infiltration of the anterior pituitary, with most of the lymphocytes being CD3-positive and 108 few being CD20-positive. In addition, no IgG4-positive cells were present (Fig. 2A–D). 109 There were no findings suggestive of IgG4-related disease [6], sarcoidosis, or neoplasia, 110 and none that were inconsistent with lymphocytic hypophysitis. No findings 111 characteristic of malignancy were found on bronchoalveolar lavage (BAL), whereas the 112 proportion of lymphocytes in the BAL fluid was elevated to 53.7%. Biopsies of the 113 patient's hilar lymph nodes by an endobronchial ultrasound-guided transbronchial needle 114 aspiration revealed non-caseating epithelioid cell granulomas, consistent with sarcoidosis 115 (Fig. 2E). His uveitis was considered to reflect systemic sarcoidosis, but no other 116 sarcoidosis lesions were identified, including in the liver and heart.

We investigated his autoantibody profile. ANA was borderlined, but the rest of routine autoantibodies were all negative (table 2). On the other hand, the presence of serum antirabphilin-3A antibody was detected by western blotting [7] (Fig. 3). Ultimately, we diagnosed lymphocytic panhypophysitis.

Because the patient had no visual field impairment and his uveitis was not severe, we continued physiological glucocorticoid replacement and local steroid treatment for the uveitis. The ongoing hormone replacement comprised hydrocortisone 15 mg/day, levothyroxine 75  $\mu$ g/day, and oral desmopressin 60  $\mu$ g/day, and the patient reported no symptoms at his most recent visit.

126

#### 127 Discussion

In the case reported herein, examination of a pituitary biopsy supported a diagnosis of LH, but a diagnosis of pulmonary sarcoidosis, made on the basis of a lymph node biopsy, suggested the presence of central nervous system sarcoidosis, which complicated the diagnosis. Ultimately, we diagnosed LPH, based on the presence of anti-rabphilin-3A
antibody alongside the biopsy findings. A few cases of comorbid sarcoidosis and
lymphocytic hypophysitis has been reported [8, 9], although no case was performed
pituitary and hilar lymph node biopsy and testing for the anti-rabphilin-3A antibody.

In general, a diagnosis of central nervous system sarcoidosis, including suprasellar lesions, is made on the basis of the clinical manifestations and biopsy findings, although biopsies are often obtained from tissues other than the pituitary gland, such as the hilar lymph nodes. The classical finding of sarcoidosis is noncaseating granulomas [10], which is not seen in the pathology of LH cases. In the present patient, we performed biopsies of both the pituitary gland and hilar lymph nodes, which facilitated a diagnosis of LPH.

142 A diagnosis of LH is confirmed by the exclusion of other types of inflammatory 143 disease in the suprasellar region. The histological findings of LH are the infiltration of the 144 adenohypophysis with lymphocytes, plasma cells, and macrophages. The T and B 145 lymphocytes that infiltrate the pituitary gland can also form lymphoid follicles with a 146 germinal center [11]. IgG4-related disease, sarcoidosis, malignant lymphoma, malignant 147 tumor metastasis, syphilis, and tuberculosis were considered as alternative causes of 148 panhypopituitarism in the present case. Diseases other than sarcoidosis could be excluded 149 on the basis of blood tests, imaging, and clinical findings. Although the pituitary biopsy 150 showed features consistent with LH, the presence of pulmonary and ocular sarcoidosis 151 might imply the presence of sarcoidosis-induced hypophysitis (Table 1), and indeed non-152 specific inflammation can be found in pituitary biopsy specimens, even if a germinoma 153 exists in the suprasellar region, because of the choice of sampling site or if a small biopsy 154 is obtained [12].

155 Sarcoidosis is a systemic granulomatous disease of unknown cause that often 156 causes lesions in the lungs, eyes, and skin [13]. It has been reported that 5%-13% of 157 patients present with neurological lesions [13-15], and of these, hypothalamic and 158 pituitary lesions have been reported in ~3% [16]. Sarcoidosis often resolves 159 spontaneously [17], but steroid treatment is often required to treat the neuropathies, 160 including lesions of the hypothalamus and pituitary. However, such treatment is often 161 unsuccessful: Anthony et al. studied 46 patients with neuropathy and poor 162 thalamic/pituitary function [18], of which 43 required treatment with steroids, but only 163 five patients improved with treatment. In the present case, bilateral enlargement of the 164 hilar lymph nodes and the results of a biopsy of these lymph nodes were consistent with 165 pulmonary sarcoidosis, but steroid treatment was not indicated because of the absence of 166 respiratory symptoms. High-dose steroid therapy is usually required for the treatment of 167 CNS sarcoidosis, but only physiological steroid replacement is recommended for the 168 treatment of LH, except if symptoms of compression owing to enlargement of the 169 pituitary are present.

170 Anti-rabphilin-3A antibody is an autoantibody that was first reported by Iwama 171 et al. in 2015[7, 19]. It has a high sensitivity of 100% for the identification of 172 pathologically diagnosed LINH and 76% for clinically diagnosed LINH, but there can be 173 false positives in healthy individuals and patients with other autoimmune diseases. 174 However, its specificity has been shown to be 100% for the differentiation of LINH from 175 neoplastic diseases (pathological diagnoses), which implies that it is clinically useful for 176 the differentiation of LINH from other diseases[7]. Even though the significance and the 177 prevalence of anti-rabphilin-3A antibody in the diagnosis of LPH has yet to be fully 178 established, the presence of the antibody in the present case definitely diagnosed as

179	lymphocytic hypophysitis with pituitary-biopsy suggests that the autoimmune process
180	other than sarcoidosis existed in the pituitary injury, and that the utility of the antibody in
181	the diagnosis of LPH.
182	
183	Conclusion
184	We have reported a case of lymphocytic panhypophysitis and anti-rabphilin-3A
185	antibody with pulmonary sarcoidosis. The utility of anti-rabphilin-3A antibody to
186	distinguish LPH from other inflammatory disease in the suprasellar region should be
187	clarified in the further case studies.
188	
189	Declarations
190	Funding: The authors did not receive support from any organization for the submitted
191	work.
192	Conflicts of interest: The authors have no relevant financial or non-financial interests to
193	disclose.
194	Availability of data and material: Not applicable.
195	Code availability: Not applicable.
196	Authors' contributions:Not applicable
197	Ethics approval:Not applicable
198	Consent to participate: Not applicable
199 200	Consent for publication: Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

## 202 Acknowledgments

203 We thank Mark Cleasby, PhD from Edanz (<u>https://jp.edanz.com/ac</u>) for editing a draft of

this manuscript.

## **References**

208	1	Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. (2005)
209		Autoimmune hypophysitis. Endocr Rev 26: 599-614.
210	2	Lupi I, Zhang J, Gutenberg A, Landek-Salgado M, Tzou SC, Mori S, Caturegli P. (2011)
211		From pituitary expansion to empty sella: disease progression in a mouse model of
212		autoimmune hypophysitis. Endocrinology 152: 4190-4198.
213	3	Tzou SC, Lupi I, Landek M, Gutenberg A, Tzou YM, Kimura H, Pinna G, Rose NR,
214		Caturegli P. (2008) Autoimmune hypophysitis of SJL mice: clinical insights from a new
215		animal model. Endocrinology 149: 3461-3469.
216	4	Lupi I, Broman KW, Tzou SC, Gutenberg A, Martino E, Caturegli P. (2008) Novel
217		autoantigens in autoimmune hypophysitis. Clin Endocrinol (Oxf) 69: 269-278.
218	5	Takao T, Nanamiya W, Matsumoto R, Asaba K, Okabayashi T, Hashimoto K. (2001)
219		Antipituitary antibodies in patients with lymphocytic hypophysitis. Horm Res 55: 288-292.
220	6	Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P. (2011) IgG4-related
221		hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 96:
222		1971-1980.
223	7	Iwama S, Sugimura Y, Kiyota A, Kato T, Enomoto A, Suzuki H, Iwata N, Takeuchi S,
224		Nakashima K, Takagi H, Izumida H, Ochiai H, Fujisawa H, Suga H, Arima H, Shimoyama
225		Y, Takahashi M, Nishioka H, Ishikawa SE, Shimatsu A, Caturegli P, Oiso Y. (2015)
226		Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis.
227		J Clin Endocrinol Metab 100: E946-954.
228	8	Hayashi H, Yamada K, Kuroki T, Katayama M, Shigemori M, Kuramoto S, Nonaka K.
229		(1991) Lymphocytic hypophysitis and pulmonary sarcoidosis. Report of a case. Am J Clin
230		Pathol 95: 506-511.
231	9	Steup-Beekman G, Zweers E. (1998) Lymphocytic hypophysitis in a 43-year-old woman.
232		The Netherlands journal of medicine 53: 76-79.
233	10	Cohen Aubart F, Galanaud D, Haroche J, Psimaras D, Mathian A, Hié M, Le-Thi Huong
234		Boutin D, Charlotte F, Maillart E, Maisonobe T, Amoura Z. (2017) [Neurosarcoidosis:
235		Diagnosis and therapeutic issues]. Rev Med Interne 38: 393-401.
236	11	Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C,
237		Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R,
238		Milian M, Petersenn S. (2015) Diagnosis of Primary Hypophysitis in Germany. J Clin
239		Endocrinol Metab 100: 3841-3849.
240	12	Pal R, Rai A, Vaiphei K, Gangadhar P, Gupta P, Mukherjee KK, Singh P, Ray N, Bhansali

241		A, Dutta P. (2020) Intracranial Germinoma Masquerading as Secondary Granulomatous
242		Hypophysitis: A Case Report and Review of Literature. Neuroendocrinology 110: 422-429.
243	13	Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T. (2008)
244		Epidemiology of sarcoidosis in Japan. Eur Respir J 31: 372-379.
245	14	Statement on sarcoidosis (1999) Joint Statement of the American Thoracic Society (ATS),
246		the European Respiratory Society (ERS) and the World Association of Sarcoidosis and
247		Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and
248		by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160: 736-
249		755.
250	15	Nozaki K, Judson MA. (2012) Neurosarcoidosis: Clinical manifestations, diagnosis and
251		treatment. Presse Med 41: e331-348.
252	16	Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW,
253		Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D. (1999) Central
254		nervous system sarcoidosisdiagnosis and management. QJM 92: 103-117.
255	17	Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Judson
256		MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, Spagnolo
257		P, Teirstein A. (2011) Defining the clinical outcome status (COS) in sarcoidosis: results
258		of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 28: 56-64.
259	18	Anthony J, Esper GJ, Ioachimescu A. (2016) Hypothalamic-pituitary sarcoidosis with
260		vision loss and hypopituitarism: case series and literature review. Pituitary 19: 19-29.
261	19	Christ-Crain M, Bichet DG, Fenske WK, Goldman MB, Rittig S, Verbalis JG, Verkman
262		AS. (2019) Diabetes insipidus. Nat Rev Dis Primers 5: 54.
263		

265 Figure captions

266

Fig. 1 Imaging results. Sagittal gadolinium-enhanced T1-weighted brain magnetic resonance image on day 1: sagittal (A) and coronal (B). (C) Chest X-ray on day 1. (D, E) Axial iodine-enhanced computerized tomography images, showing bilateral enlargement of the hilar lymph nodes

271

272 Fig. 2 Histology and immunohistochemistry of biopsy specimens demonstrated mild 273 lymphocytic infiltration of the anterior pituitary, with most of the lymphocytes being 274CD3-positive and few being CD20-positive. (A) Hematoxylin and eosin staining of the 275 pituitary. Scale bar: 50 µm. (B) CD3 immunostaining of the pituitary. Scale bar: 50 µm. 276 (C) CD20 immunostaining of the pituitary. Scale bar: 50 µm. (D) IgG4 immunostaining 277 of the pituitary. Scale bar: 50 µm. There were no findings suggestive of IgG4-related disease. (E) Hematoxylin and eosin staining of the hilar lymph nodes. Scale bar: 100 278279 μm.

280

Fig. 3 Detection of anti-rabphilin-3A antibodies by Western blotting.

282 Recombinant full-length human rabphilin-3A expression was evaluated in HEK293FT

cells transfected with the human rabphilin-3A gene (RPH3A + HEK293FT, left lanes) or

with the empty vector (HEK293FT, right lanes) by probing with serum from the present

285 patient (patient), from a patient who was diagnosed with LINH previously (positive

286 control patient), or from a patient who was diagnosed with craniopharyngioma

- 287 previously (negative control patient). The arrowhead indicates the presence of anti-
- 288 rabphilin-3A antibodies. The dashed arrowhead indicates the absence of anti-rabphilin-
- 289 3A antibodies. Recombinant full-length human rabphilin-3A expressed in HEK293FT
- 290 cells was also probed with an anti-V5 antibody as positive control (Anti-V5 antibody) in

the first lane from the left.

<cbc></cbc>				Cl	101	mEq/L	101-108 *	<endocri< th=""><th>nology&gt;</th><th></th><th></th><th><urine te<="" th=""><th>sting&gt;</th><th></th></urine></th></endocri<>	nology>			<urine te<="" th=""><th>sting&gt;</th><th></th></urine>	sting>	
WBC	8.5×10 <sup>3</sup>	/ µL	3.3-8.6 *	Ca	9.1	mg/dL	8.8-10.1 *	ACTH	6.53	pg/mL	7.2-63.3 *	pН	5.0	4.5-8.5 *
RBC	4.5×10 <sup>6</sup>	/µL	4.3-5.5 *	Р	3.7	mg/dL	2.7-4.6 *	Cortisol	1.2	µg/dL	2.9-19.4 *	Protein	-	_ *
Hb	13.2	g/dL	13.7-16.8 *	CRP	0.11	mg/dL	0-0.14 *	GH	0.33	ng/mL	0.0-0.17 *	Glucose	-	_ *
Ht	39	%	40.7-50.1 *	TG	160	mg/dL	40-234 *	IGF-1	63	ng/mL	81-235 *	Ketone	-	_ *
Plt	28.7×10 <sup>4</sup>	/µL	15.8-34.8 *	HDL-C	41	mg/dL	38-90 *	LH	<1.0	mIU/mL	2.2-8.4 *	Blood	-	_ *
< Bioch	emistry>			LDL-C	181	mg/dL	65-163 *	FSH	<1.0	mIU/mL	1.8-12.0 *			
ТР	7.4	g/dL	6.6-8.1 *	Glucose	120	mg/dL	73-109 *	Testo	<12.0	ng/dL	131-871 *			
Alb	4.1	g/dL	4.1-5.1 *	HbA1c	6.3	%	4.9-6.0 *	ADH	0.6	pg/mL				
T-bil	0.6	mg/dL	0.4-1.5 *	ACE	16.9	U/L	8.3-21.4 *	TSH	0.64	μU/mL	0.34-4.22 *			
AST	33	U/L	13-30 *	sIL-2 R	578	U/mL	0-613 *	FT3	1.93	pg/mL	2.24-3.94 *			
ALT	24	U/L	10-42 *	IgA	273	mg/dL	93-393 *	FT4	0.57	ng/dL	0.77-1.59 *			
γ-GTP	16	U/L	13-64 *	IgM	48	mg/dL	33-183 *	Renin	< 0.2	ng/mL/h	0.2-3.9 *			
BUN	11	mg/dL	8-20 *	IgG	1662	mg/dL	861-1747 *	Ald	76	pg/mL	36-240 *			
Cre	1.16	mg/dL	0.65-1.07 *	IgG4	77.9	mg/dL	11.0-121.0 *							
eGFR	51.4	ml/min/1.73m <sup>2</sup>		RPR	-		_ *							
Na	136	mEq/L	138-145 *	TPLA	-		_ *							
K	4.0	mEq/L	3.6-4.8 *	TSPOT.TB	-		_ *							

**Table 1.** Laboratory findings at the admission

pH: power of hydrogen, CBC: complete blood count, WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, Plt: platelet, TP: total protein, Alb: albumin, T-bil: total bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase,  $\gamma$ -GTP: gamma glutamyl transpeptidase, BUN: blood urea nitrogen, Cre: creatinine, eGFR: estimated glomerular filtration rate, CRP: c-reactive protein, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, ACE: angiotensin-converting enzyme, sIL-2 R: soluble interleukin-2 receptor, IgA: immunoglobin A, IgM : immunoglobin M, IgG: immunoglobin G, IgG 4: immunoglobin G4, RPR: rapid plasma reaction, TPLA: toreponema pallidum antigen method, ACTH: adrenocorticotropic hormone, GH: growth hormone, IGF-1: insulin-like growth factor-1, LH: luteinizing hormone, FSH: follicle stimulating hormone, Testo: Testosterone, ADH: antidiuretic hormone, TSH: thyroid stimulating hormone, FT3: free triiodothyronine, FT4: free thyroxine, Ald: Aldosterone \* nomal range

 Table 2. Autoantibody profile

J 1			
Antinuclear antibody	80	times	<40 *
Anti SS-A antibody	3.8	INDEX	<10 *
Anti SS-B antibody	0.7	INDEX	<10 *
Anti β2GP1 antibody	< 0.7	U/mL	<3.5 *
Anti TPO antibody	<3.0	IU/mL	0-5.6 *
Anti TG antibody	<3.0	IU/mL	0-4.11 *

SS-A:Sjogren syndrome-A, SS-B:Sjogren syndrome-B, GPI:glycoprotein 1, TPO: thyroperoxidase, TG: thyroglobulin.

\* nomal range

# Figure. 1





Figure. 2






Figure. 3

